Palatin Technologies (PTN) Non Operating Income (2010 - 2022)
Palatin Technologies' (PTN) quarterly Non Operating Income came in at -$512245.0 in Q4 2022, down 117.71% YoY from $2.9 million in Q4 2021, and down 203.01% on a QoQ basis from $497263.0 in Q3 2022.
Palatin Technologies (PTN) Non Operating Income (2010 - 2022) Analysis & Trends
Palatin Technologies (PTN) has 13 years of Non Operating Income data on file, last reported at -$512245.0 in Q4 2022.
- Quarterly Non Operating Income fell 117.71% year-over-year to -$512245.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $507317.0 (up 29.13% YoY) and the FY2022 annual result came in at $390149.0, up 283.69% from the prior year.
- Non Operating Income slipped to -$512245.0 in Q4 2022, from $497263.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $756584.0 in Q1 2021 to a low of -$742073.0 in Q4 2020.
- A 5-year average of $68621.8 and a median of $37500.0 in 2019 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2018 — Non Operating Income plunged 13233.33% — and 2019, when it soared 21181.08%.
- Tracing PTN's Non Operating Income over 5 years: stood at $8000.0 in 2018, then jumped by 4868.5% to $397480.0 in 2019, then slumped by 286.69% to -$742073.0 in 2020, then surged by 68.29% to -$235288.0 in 2021, then tumbled by 117.71% to -$512245.0 in 2022.
- The last three Non Operating Income figures came in at -$512245.0 (Q4 2022), $497263.0 (Q3 2022), and $333472.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -512,245.00 |
| Sep 30, 2022 | 497,263.00 |
| Jun 30, 2022 | 333,472.00 |
| Mar 31, 2022 | 188,827.00 |
| Dec 31, 2021 | -235,288.00 |
| Sep 30, 2021 | 103,138.00 |
| Jun 30, 2021 | -231,551.00 |
| Mar 31, 2021 | 756,584.00 |
| Dec 31, 2020 | -742,073.00 |
| Sep 30, 2020 | 4,646.00 |
| Jun 30, 2020 | 91,000.00 |
| Mar 31, 2020 | 331,007.00 |
| Dec 31, 2019 | 397,480.00 |
| Sep 30, 2019 | 361,603.00 |
| Jun 30, 2019 | 39,000.00 |
| Mar 31, 2019 | 36,000.00 |
| Dec 31, 2018 | 8,000.00 |
| Sep 30, 2018 | -54,000.00 |
| Jun 30, 2018 | -185.00 |
| Mar 31, 2018 | -241.00 |